← Leaderboards
Stephen W. Fesik
Vanderbilt University
$5,661,476
Attributed
$5,661,476
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,661,476 · 5
By mechanism
DP1$3,817,923 · 2
R01$1,302,581 · 1
P50$375,570 · 1
P30$165,402 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- David K Cortez$25,955,406
- Walter J Chazin$29,538,014
- Hassane S McHaourab$22,963,634
- P Jeffrey Conn$37,782,937
- David Sung-Wen Yu$7,962,579
Others in their field
Top investigators on “Drug Discovery”
- David Heimbrook · Leidos Biomedical Research, Inc.$369,513,553
- Leonard Freedman · Leidos Biomedical Research, Inc.$255,277,443
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ralph Parchment · Leidos Biomedical Research, Inc.$137,717,670
- Daniel Ernest Ford · Johns Hopkins University$137,014,543
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
Research focus
Drug DiscoveryDesignPharmaceutical PreparationsStructureLeadProtein Protein InteractionBaseProteinsBiologyPathway InteractionsCancer CellAffinitySmall MoleculeTechnologyCellsTumorMalignant NeoplasmsNew Therapeutic TargetResponseInhibitor/AntagonistFutureBinding (Molecular Function)Computerized ToolsAffect
Grant awards (12)
Project 3: Characterization of Beta-Catenin Degraders for the Treatment of Colorectal Cancer$375,570
P50 · FY2025 · CA · contact PI
Signal Transduction and Chemical Biology Research Program$82,784
P30 · FY2021 · CA · contact PI
Signal Transduction and Chemical Biology Research Program$82,618
P30 · FY2020 · CA · contact PI
Validating the protein binding domain of replication protein A as a cancer target$325,775
R01 · FY2017 · CA · contact PI
Validating the protein binding domain of replication protein A as a cancer target$325,775
R01 · FY2016 · CA · contact PI
Validating the protein binding domain of replication protein A as a cancer target$325,775
R01 · FY2015 · CA · contact PI
Expanding the druggable genome$749,034
DP1 · FY2014 · CA · contact PI
Validating the protein binding domain of replication protein A as a cancer target$325,256
R01 · FY2014 · CA · contact PI
Expanding the druggable genome$749,034
DP1 · FY2013 · CA · contact PI
Expanding the druggable genome$772,200
DP1 · FY2012 · CA · contact PI
Expanding the druggable genome$772,200
DP1 · FY2011 · OD · contact PI
Expanding the druggable genome$775,455
DP1 · FY2010 · OD · contact PI